HUP0100520A1 - Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok - Google Patents

Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok

Info

Publication number
HUP0100520A1
HUP0100520A1 HU0100520A HUP0100520A HUP0100520A1 HU P0100520 A1 HUP0100520 A1 HU P0100520A1 HU 0100520 A HU0100520 A HU 0100520A HU P0100520 A HUP0100520 A HU P0100520A HU P0100520 A1 HUP0100520 A1 HU P0100520A1
Authority
HU
Hungary
Prior art keywords
compounds
inhibitors
bone resorption
general formula
cell adhesion
Prior art date
Application number
HU0100520A
Other languages
English (en)
Inventor
Sarah Catherine Bodary
Denis Carniato
Robert Andrew Cuthbertson
Thomas Gadek
Jean-Francois Gourvest
Jochen Knolle
Robert Mcdowell
Anuschirwan Peyman
Karl-Heinz Scheunemann
David William Will
Original Assignee
Aventis Pharma Deutschland Gmbh.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh., Genentech, Inc. filed Critical Aventis Pharma Deutschland Gmbh.
Publication of HUP0100520A1 publication Critical patent/HUP0100520A1/hu
Publication of HUP0100520A3 publication Critical patent/HUP0100520A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya (I) általános képletű szulfonamidszármazékok,amelyek csontfelszívódás és sejt összetapadás inhibitorok. Az (I)általános képletben R1, R2, R4, R5 és R6 jelentése az igénypontokbanmegadott. A találmány kiterjed a vegyületek fiziológiailag elfogadhatósóira és prodrugjaira. Az (I) általános képletű vegyületek értékesgyógyhatású vegyületek, vitronektin receptor antagonisták és gátoljáka csontfaló sejtek által előidézett csontfelszívódást és sejtösszetapadást. Alkalmasak például olyan betegségek megelőzésére ésgyógyítására, amelyeket részben nem kívánt mértékű csontfelszívódás,pl. oszteoporózis idéz elő. Kiterjed a találmány továbbá az (I)általános képletű vegyületek előállítására és különösen gyógyászatihatóanyagként történő felhasználására, illetve a vegyületekettartalmazó gyógyszerkészítményekre. Ó
HU0100520A 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion HUP0100520A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1248998A 1998-01-23 1998-01-23
PCT/EP1999/000242 WO1999037621A1 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Publications (2)

Publication Number Publication Date
HUP0100520A1 true HUP0100520A1 (hu) 2001-07-30
HUP0100520A3 HUP0100520A3 (en) 2002-11-28

Family

ID=21755208

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100520A HUP0100520A3 (en) 1998-01-23 1999-01-16 Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Country Status (25)

Country Link
EP (1) EP1049677A1 (hu)
JP (1) JP2002501054A (hu)
KR (1) KR20010034319A (hu)
CN (1) CN1177832C (hu)
AP (1) AP1269A (hu)
AR (1) AR014456A1 (hu)
AU (1) AU752882B2 (hu)
BG (1) BG104630A (hu)
BR (1) BR9907735A (hu)
CA (1) CA2318221A1 (hu)
EA (1) EA003102B1 (hu)
HR (1) HRP20000493A2 (hu)
HU (1) HUP0100520A3 (hu)
ID (1) ID26219A (hu)
IL (1) IL137423A0 (hu)
NO (1) NO318795B1 (hu)
NZ (1) NZ505613A (hu)
PL (1) PL341871A1 (hu)
SK (1) SK10632000A3 (hu)
TR (1) TR200002160T2 (hu)
TW (1) TWI247742B (hu)
UA (1) UA63990C2 (hu)
WO (1) WO1999037621A1 (hu)
YU (1) YU47200A (hu)
ZA (1) ZA99476B (hu)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100506A4 (en) * 1998-07-29 2002-06-26 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
EP1028114A1 (en) 1999-02-13 2000-08-16 Aventis Pharma Deutschland GmbH Novel guanidine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1070707A1 (en) * 1999-07-21 2001-01-24 Aventis Pharma Deutschland GmbH 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
US6849639B2 (en) 1999-12-14 2005-02-01 Amgen Inc. Integrin inhibitors and their methods of use
EP1108721A1 (en) 1999-12-15 2001-06-20 Aventis Pharma Deutschland GmbH Thienylalanine derivatives as inhibitors of cell adhesion
AU2207001A (en) * 1999-12-24 2001-07-09 Smithkline Beecham Plc Novel compounds and process
FR2808798A1 (fr) * 2000-05-09 2001-11-16 Hoechst Marion Roussel Inc Nouveaux derives antagonistes du recepteur de la vitronectine
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
RU2393154C2 (ru) 2004-03-24 2010-06-27 Йерини Аг Новые соединения для ингибирования ангиогенеза и их применение
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
GB0412553D0 (en) * 2004-06-04 2004-07-07 Univ Aberdeen Therapeutic agents for the treatment of bone conditions
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
HRP20211877T1 (hr) 2014-12-17 2022-03-04 Pimco 2664 Limited Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU701776B2 (en) * 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
JP3895792B2 (ja) * 1995-12-08 2007-03-22 プロスケリア・エス・ア・エス 骨形成促進剤

Also Published As

Publication number Publication date
IL137423A0 (en) 2001-07-24
TR200002160T2 (tr) 2001-07-23
NO318795B1 (no) 2005-05-09
PL341871A1 (en) 2001-05-07
AP2000001863A0 (en) 2000-09-30
AR014456A1 (es) 2001-02-28
CN1177832C (zh) 2004-12-01
WO1999037621A1 (en) 1999-07-29
UA63990C2 (uk) 2004-02-16
KR20010034319A (ko) 2001-04-25
HUP0100520A3 (en) 2002-11-28
EP1049677A1 (en) 2000-11-08
AP1269A (en) 2004-04-03
ZA99476B (en) 1999-08-05
EA200000785A1 (ru) 2001-02-26
TWI247742B (en) 2006-01-21
CA2318221A1 (en) 1999-07-29
AU752882B2 (en) 2002-10-03
SK10632000A3 (sk) 2001-02-12
BR9907735A (pt) 2000-10-17
EA003102B1 (ru) 2002-12-26
NZ505613A (en) 2002-11-26
YU47200A (sh) 2002-11-15
BG104630A (en) 2001-04-30
JP2002501054A (ja) 2002-01-15
HRP20000493A2 (en) 2001-06-30
CN1293662A (zh) 2001-05-02
NO20003765L (no) 2000-09-25
NO20003765D0 (no) 2000-07-21
AU2518199A (en) 1999-08-09
ID26219A (id) 2000-12-07

Similar Documents

Publication Publication Date Title
HUP0100520A1 (hu) Csontfelszívódást és sejtösszenövést gátló új szulfonamidszármazékok
DE602004007239D1 (de) 4-AMINOTHIENOÄ2,3-dÜ PYRIMIDIN -6-CARBONITRIL-DERIVATIVE ZUR VERWENDUNG ALS PDE7 INHIBITOREN
DE60315492D1 (de) Medizinisch verwendbare arylethanolamin verbindungen
TR200100894T2 (tr) Aril ikameli propanolamin türevleri, imalat yöntemleri, ilaç maddeleri, kullanımları.
DE69713526D1 (de) Lösliche prodrugs von paclitaxel
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
RU2006109467A (ru) Способы лечения рака с использованием ингибиторов hdac
YU65804A (sh) Nova heterociklična jedinjenja aktivna kao inhibitori beta-laktamaze
EA200500088A1 (ru) Трициклические модуляторы ядерного рецептора стероидного гормона
DE69912313D1 (de) Colchinolderivate als gefässschädigende mittel
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
BG104544A (en) Novel acylguanadine derivatives as inhibitors of bone resorption and as vitronectin receptor antagonists
ATE486587T1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
TR199701647A2 (xx) �kame edilmi� purin t�revleri,bunlar�n imalat usul�
ATE507226T1 (de) 1,3,4-oxadiazol-2-one als ppar-delta-modulatoren und deren verwendung
HUP0402577A2 (hu) Citoszol foszfolipáz A2 inhibitor hatású indolszármazékok, eljárás előállításukra
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
MXPA06003374A (es) Derivados de bencimidazolona y quinazolinona como agonistas en receptores semejantes al receptor opioide 1 de humano.
ID29025A (id) Fenilalkenoilguanidina-fenilalkenoilguanidina yang disubstitusi asam empedu, proses pembuatannya, penggunaannya sebagai obat atau diaknostik dan obat-obat yang mengandungnya
DE602005017629D1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis
SE9901572D0 (sv) New compounds

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees